Alnylam Pharmaceuticals Inc (ALNY)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$285.32

Buy

$285.00

arrow-up$1.91 (+0.67%)

Prices updated at 17 May 2025, 00:55 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
NASDAQ
arrow-up0.52%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Ms. Amy W. Schulman
CEO
Dr. Yvonne L Greenstreet, MB.Ch.B.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
2,230
Head office
675 West Kendall Street
Cambridge
United States
02142
mobile
+1 617 551-8200
letter
INVESTORS@ALNYLAM.COM
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Dr. Phillip A. Sharp,PhD
Independent Director
0.08m
Dr. Elliott Sigal, M.D.,PhD
Independent Director
0.08m
Mr. Michael W. Bonney
Director
0.06m
Dr. Margaret A. Hamburg, M.D.
Independent Director
0.07m
Ms. Amy W. Schulman
Chairman of the Board
0.14m
Dr. Yvonne L Greenstreet, MB.Ch.B.
Director and Chief Executive Officer
1.25m
Mr. David E.I. Pyott, M.B.A.,M.D.
Independent Director
0.08m
Dr. Dennis A. Ausiello, M.D.
Independent Director
0.08m
Mr. Peter N. Kellogg
Independent Director
-
Dr. Olivier Raymond Brandicourt, M.D.
Independent Director
0.08m
Mr. Jeffrey V. Poulton
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
0.69m
Dr. Carolyn R. Bertozzi, PhD
Independent Director
0.04m
Ms. Colleen F. Reitan
Independent Director
0.09m
Dr. Pushkal P. Garg, M.D.
Chief Medical Officer and Executive Vice President, Development and Medical Affairs
0.68m
Mr. Tolga Tanguler
Chief Commercial Officer
0.63m
Mr. Kevin Joseph Fitzgerald, PhD
Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development
0.59m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Capital Research and Management Company23,186,024
Capital Group19,693,004
Capital World Investors16,749,623
FMR Inc15,309,860
Fidelity Management and Research Company15,309,860

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
12 Dec 2024-
12 Dec 2024-
12 Dec 2024-
12 Dec 2024-
12 Dec 2024-
12 Dec 2024-
12 Dec 2024-
26 Nov 2024-
26 Nov 2024-
26 Nov 2024-
26 Nov 2024-
26 Nov 2024-
25 Nov 2024-
26 Nov 2024-
26 Nov 2024-
26 Nov 2024-
26 Nov 2024-
26 Nov 2024-
25 Nov 2024-
26 Nov 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.